Wedbush raised the firm’s price target on Astria Therapeutics (ATXS) to $28 from $27 and keeps an Outperform rating on the shares. The firm says that all development timelines remain on track for lead program navenibart in HAE, with the Phase 3 ALPHA-ORBIT study underway and incorporating two regimens. Potential top-line results remain on track for early 2027. Given the parallels between Takhzyro and navenibart, Wedbush anticipates strong patient interest in the study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics Advances Clinical Trials and Financials
- Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating
- Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating
- Buy Rating for Astria Therapeutics: Promising Clinical Advancements and Strong Financial Position
- Astria Therapeutics, Inc. (ATXS) Q4 Earnings Cheat Sheet